TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients aged ≥12 years from the date of informed consent~* Confirmed diagnosis of CF at screening~* Confirmed EPI by historical (within past 12 months) CFA \<70% without use of PERTs or current fecal elastase \<50 µg/g stool at screening~* Currently receiving PERT with a commercially available pancreatic enzyme~* Currently on stable treatment with proton pump inhibitors or H2 receptor antagonists~* Clinically stable condition without evidence of acute respiratory disease or any other acute condition~Exclusion Criteria:~* History of fibrosing colonopathy~* History of significant bowel resection, in the opinion of the investigator, or solid organ transplant~* History of being refractory to pancreatic enzyme replacement~* Current diagnosis or history of distal intestinal obstruction syndrome~* Current diagnosis of small intestinal bacterial overgrowth, ileus or acute abdomen~* A body mass index percentile \<10%

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Burlulipase (Type: EXPERIMENTAL): Burlulipase orally, per meal
- Placebo (Caramel in sterile water) (Type: PLACEBO_COMPARATOR): Placebo orally, per meal

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Multicentric Randomized Study of Glivec® in Advanced GIST Expressing C-kit: Interruption After 5 Years vs Maintenance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients 18 years of age or over.~2. Histologically documented diagnosis of malignant GIST.~3. Immunohistochemical documentation of c-kit (CD117) expression either by the primary tumor or metastases using the DAKO assay.~4. Performance status 0,1, 2, 3 (ECOG)~5. Adequate end organ function, defined as the following: total bilirubin \< 1.5 x ULN, SGOT and SGPT \< 2.5 x UNL (or \< 5 x ULN if hepatic metastases are present), creatinine \< 1.5 x ULN, ANC \> 1.0 x 109/L, platelets \> 100 x 109/L.~6. Female patients of child-bearing potential must have negative pregnancy test within 7 days before initiation of study drug dosing. Post menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Female patients of reproductive potential must agree to employ an effective barrier method of birth control throughout the study and for up to 2 weeks (according to updated Invest. Brochure) following discontinuation of study drug.~7. Written, voluntary, informed consent.~Exclusion Criteria:~1. Patient has another malignant tumor in CR\<3 years (except if the other primary malignancy is inactive and not requiring active intervention). Previous basal cell skin cancer or a cervical carcinoma in situ are allowed.~2. Patient with Grade III/IV cardiac problems as defined by the New York Heart Association Criteria. (i.e., congestive heart failure, myocardial infarction within 6 months of study)~3. Female patients who are pregnant or breast-feeding.~4. Patient has a known diagnosis of human immunodeficiency virus (HIV) infection.~5. Patients received chemotherapy within 2 weeks prior to study entry, unless the disease is rapidly progressing~6. Patients had a major surgery within 2 weeks prior to entry study~7. Patient with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent.~8. Previous treatment with Glivec®

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- interruption of Glivec® (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Use of N-Acetylcysteine During Liver Procurement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* all consecutive subjects with chronic liver disease undergoing first Liver Transplantation receiving deceased donor livers~Exclusion Criteria:~* recipients with acute liver disease;~* paediatric patients or adult patients receiving a liver from a paediatric donor;~* patients undergoing multiple-organ transplantation;~* patients undergoing re-transplantation of the Liver;~* patients undergoing living donor Liver Transplantation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NAC procurement protocol (Type: EXPERIMENTAL): The allocated organ, in addition to the standard procedure, was treated with a systemic NAC infusion before initiating the liver harvesting procedure, and a loco-regional infusion into the portal vein before cross-clamping.
- Standard procurement procedure (Type: NO_INTERVENTION): Allocated organ was treated according to the centre's standard procurement procedure: a modified double perfusion technique, where donor livers are gravity-perfused in situ via the aorta and portal vein with Celsior solution at 4 °C. After hepatectomy, donor livers were further perfused at the back-table with Celsior solution and then stored in conventional bags containing the same solution at 4 °C until transplantation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Stay Connected: Testing an Intervention to Combat Coronavirus-related Social Isolation Among Older Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Older Adult Participants~Inclusion Criteria:~1. 60 years of age or older~2. Physical and cognitive ability to complete interviews by phone or using video-chat technology (e.g., Zoom)~3. English speaking~4. Resident of participating Seattle-area senior living communities or member of Seattle-area senior centers~5. Ability to provide consent~6. Score of 5 or higher on Patient Health Questionnaire (PHQ-9) or score of 5 or higher on Generalized Anxiety Disorder Scale (GAD-7) or score of 6 or higher on University of California Los Angeles (UCLA) Loneliness Scale~7. No suicidal ideation~Exclusion Criteria:~1. Under the age of 60~2. Inability to physically and/or cognitively consent and/or participate in study procedures via phone, computer, and/or video call~3. Non-English speaking~4. Scores below inclusion cut-offs on PHQ-9, GAD-7, and UCLA Loneliness Scale~Staff Participants Inclusion Criteria~1. English-speaking~2. Staff members in administration, social work, and/or activities department in Seattle area senior living communities or senior centers~3. Physical ability to complete training in intervention and complete questionnaires by phone, computer, or video-chat technology~Exclusion Criteria~1. Non-English speaking~2. Unable to physically or cognitively consent and/or participate in study procedures via phone, computer, and/or video call (e.g., Zoom)

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stay Connected (Type: EXPERIMENTAL): Menu-driven set of strategies to combat loneliness, anxiety and depression in older adults
- Treatment as usual (Type: ACTIVE_COMPARATOR): Treatment as usual in these practice settings typically includes regular check-in calls and offering resources and referrals

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Does Intraoperative Clonidine Reduce Post Operative Agitation in Children?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* scheduled for surgery with Sevoflurane as the choice of anesthesia.~Exclusion Criteria:~* ASA classification \>2~* Premedication with Clonidine~* Ex-premature (born before week 37+0 AND \<60 weeks old)~* Intubated before anaesthesia and/or no plans for extubation after anaesthesia.~* Critical illness with haemodynamic instability.~* Active bleeding.~* Cancer.~* Cardiac diseases including arrhythmias.~* Malignant hyperthermia.~* Mental retardation.~* Neurological illness with agitation-like symptoms.~* Weight \>50 kg.~* Allergy to Clonidine.~* Patients treated with methylphenidate / Concerta.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Clonidine : injection og 3 micg/kg IV during the operation.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo : injection og equal amount of NaCl IV during the operation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Measurement of Anti-Androgen Response Using Fluorine-18 Fluorocholine PET/CT in Androgen-Insensitive Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Provision of written informed consent.~2. Men, over 18 years of age, with histologically-confirmed diagnosis of prostate cancer~3. History of treatment by complete androgen blockade for greater than 3 months prior to enrollment~4. Serum testosterone level \< 50 ng/ml. Castrate testosterone levels must be from orchiectomy or current therapy with leutinizing hormone-releasing hormone agonist.~5. Progressive disease evidenced by two consecutive rises in prostate specific antigen (PSA) above a nadir value, with the absolute value of the latest PSA \> 2. 0 ng/ml.~6. Patient will be undergoing a therapeutic intervention under the supervision of his treating physician (urologist, oncologist).~Exclusion Criteria:~1. Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or superficial transitional cell carcinoma of the bladder.~2. Serious underlying medical conditions that would otherwise impair the patient's ability to undergo imaging.~3. Patient weighs over 350 lbs (due to scanner weight limit).~4. Clinical life expectancy \< 12 weeks.~5. Participated in other radioactive drug studies where estimated total cumulative dose within 1 year is \> 0.05 Sievert for whole body, active blood-forming organs, eye lens, gonads, or 0.15 Sievert for other organs.~6. Concurrent Therapy. Allowed: prior hormonal therapy; concurrent leuteinizing hormone releasing hormone (LHRH) agonist; prior surgery; prior or concurrent bisphosphonate. Not allowed: concurrent anti-androgen or secondary hormonal therapy, prior or concurrent chemotherapy, concurrent radiotherapy or radioisotope therapy (e.g., strontium). Other: Prior radiotherapy or radioisotope therapy must be \> 12 weeks since last treatment.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Single Arm (Type: EXPERIMENTAL): Fluorine-18 fluorocholine IV in conjunction with PET/CT imaging, up to 3 doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 4-methylpyrazole and Acetaminophen Metabolism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy~* No APAP use in previous 2 weeks~* No ingestion of alcohol or drugs that affect CYP 2E1 over previous 5 days~* No allergy to APAP or fomepizole~* BMI \< 29~Exclusion Criteria:~* Pregnant or lactating~* History of alcohol abuse~* Allergy to APAP or fomepizole~* Screening LFTs above normal range

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- A (Type: EXPERIMENTAL): Oral APAP and IV Fomepizole.
- B (Type: ACTIVE_COMPARATOR): Oral APAP.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Stem Cell Fistula Plug in Perianal Crohn's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Males and females 18-65 years of age.~* Residents of the United States.~* Crohn's disease with single or multiple draining complex perianal fistulae (definition as below) for at least three months despite standard therapy (definition below).~* Concurrent therapies with corticosteroids, 5-ASA drugs, thiopurines, MTX, antibiotics, and anti-TNF therapy are permitted.~* All patients should have undergone a colonoscopy in last 12 months to rule out malignant or premalignant condition~* Have no contraindications to MR evaluations: e.g. pacemaker or magnetically active metal fragments, claustrophobia~* Ability to comply with protocol~* Competent and able to provide written informed consent~* Must have failed standard medical therapy including anti-TNF agents~Exclusion Criteria~* Inability to give informed consent.~* Clinically significant medical conditions within the six months before administration of MSCs: e.g. myocardial infarction, active angina, congestive heart failure or other conditions that would, in the opinion of the investigators, compromise the safety of the patient.~* Specific exclusions: Evidence of hepatitis B, C, or HIV~* History of cancer including melanoma (with the exception of localized skin cancers)~* Investigational drug within thirty (30) days of baseline~* A resident outside the United States~* Pregnant or breast feeding.~* History of clinically significant auto-immunity (other than Crohn's disease) or any previous example of fat-directed autoimmunity~* Previous allergic reaction to a perianal fistula plug.~* If liposuction is not technically feasible~* Allergic to local anesthetics~* Pregnant patients or trying to become pregnant.~* Non-enterocutaneous tracts (ie recto-vaginal, entero-vesicular)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): Only 1 arm: treatment with MSC-AFP

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Pain Control in Different Bupivacaine Dose in Periarticular Injection in Bilateral Total Knee Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged more than 18 years old~* American society of anesthesiologists physical status classification 1-3~* Undergoing bilateral total knee arthroplasty with spinal anesthesia and single shot bilateral adductor canal block~Exclusion Criteria:~* Allergy to bupivacaine~* Body weight less than 50 kilograms~* Hepatic disease~* Coagulopathy~* Creatinine clearance less than 60 ml/min~* Uncontrolled cerebrovascular disease~* Hematocrit less than 35%

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- bupivacaine 100 mg (Type: EXPERIMENTAL): bupivacaine 100 mg ketorolac 30 mg epinephrine 400 mcg add Normal saline solution(NSS) to 80 ml divided to two syringes for bilateral periarticular infiltration
- bupivacaine 200 mg (Type: ACTIVE_COMPARATOR): bupivacaine 200 mg ketorolac 30 mg epinephrine 400 mcg add NSS to 80 ml divided to two syringes for bilateral periarticular infiltration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Galantamine-CR and Cognitive Dysfunction in Bipolar Disorder

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* DSM-IV diagnostic criteria for bipolar disorder~* men or women aged 18-65~* a baseline Hamilton-D17 score of \< 10 at screen visit~* a baseline YMRS score of \< 10 at screen visit~* no acute episodes of depression or mania for the previous 12 weeks.~* written informed consent~Exclusion Criteria:~* Subjects with current suicidal ideation~* Pregnant women or women of childbearing potential~* Serious or unstable medical illness, including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic or hematologic disease; History of seizure disorder, brain injury, any history of known neurological disease (multiple sclerosis, degenerative disease such as ALS, Parkinson disease and any movement disorders, etc)~* History or current diagnosis of any of the following DSM-IV psychiatric illnesses: organic mental disorder, schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorders not otherwise specified, major depressive disorder, patients with mood congruent or mood incongruent psychotic features, patients with substance dependence disorders, including alcohol, active within the last 12 months~* History of multiple adverse drug reactions~* Patients with mood congruent or mood incongruent psychotic features Subjects who are active smokers or who stopped smoking less than 3 months prior to enrollment; Clinical or laboratory evidence of hypothyroidism~* Patients who have had an episode of acute depression or mania during the 12 weeks prior to enrollment~* Patients who have had electroconvulsive therapy (ECT) within the 6 months preceding enrollment~* Patients with physical contraindications to magnetic resonance spectroscopy (ferrous surgical clips, cardiac pacemakers, ferrous prosthesis)~* Patients taking any of the following medications: other cholinesterase inhibitors, succinylcholine, neuromuscular blocking agents, cholinergic agonists (e.g., bethanechol), cimetidine, ketoconazole, erythromycin, fluoxetine, paroxetine, and fluvoxamine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have type 2 diabetes mellitus for at least 6 months~* Have been taking metformin and/or a sulfonylurea for at least 3 months before screening and have been on a stable therapeutic dose for at least 8 weeks~* Glycosylated hemoglobin (HbA1c) value of ≥7.0% to ≤11.0%~* Adult men or adult non-pregnant, non-breastfeeding women~* Body Mass Index (BMI) of ≥19.0 to ≤35.0 kilograms/square meter (kg/m\^2)~* Stable weight (±5%) ≥3 months prior to screening~Exclusion Criteria:~* Have type 1 diabetes mellitus~* Have previous treatment with a glucagon-like peptide-1 (GLP-1) receptor agonist, GLP-1 analog, or any other incretin mimetic~* Have treatment with dipeptidyl peptidase-IV (DPP-IV) inhibitor, an alpha-glucosidase inhibitor (AGI), thiazolidinedione (TZD), or glinide~* Have gastric emptying abnormality~* Have cardiac disorder defined as unstable angina, myocardial infarction, coronary artery bypass graft surgery, percutaneous coronary intervention, heart failure, arrhythmia, transient ischemic attack, or stroke~* Have poorly controlled hypertension (systolic blood pressure above 160 millimeter of mercury\[mmHg\] or diastolic blood pressure above 95 mmHg)~* Have impaired liver function~* Have impaired kidney function~* Have history of chronic pancreatitis or acute pancreatitis~* Have a serum calcitonin ≥20 picograms per milliliter (pg/mL)~* Have a personal or family history of medullary C-cell hyperplasia, focal hyperplasia, carcinoma, or multiple endocrine neoplasia type 2 (MEN 2)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1.5 mg Dulaglutide (Type: EXPERIMENTAL): 1.5 milligrams (mg) dulaglutide administered as one subcutaneous (SC) injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea for up to 52 weeks. Participants are blinded to the dulaglutide dose.
- 0.75 mg Dulaglutide (Type: EXPERIMENTAL): 0.75 mg Dulaglutide administered as one SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea for up to 52 weeks. Participants are blinded to the dulaglutide dose.
- Insulin Glargine (Type: ACTIVE_COMPARATOR): Insulin glargine administered based on fasting blood glucose concentrations per the dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and /or a sulfonylurea for up to 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete